Correlates and economic outcomes of proton pump inhibitor use by routes in intensive care unit patients

Jayashri Sankaranarayanan, Tom Reardon, Keith M. Olsen

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives were to evaluate correlates, and economic outcomes of proton pump inhibitor (PPI) use by route in the intensive care unit from an institutional-payer perspective. A 13-month retrospective study of electronic medical records was conducted of 534 adult (≥19 year-old) intensive care unit patients receiving a PPI (39% enteral-only, 34% parenteral-only, 27% both-route) in a Midwest USA academic medical center. Possible cost-savings with sensitivity analysis were estimated as differences in drug costs (US dollars) between switch eligible parenteral and alternate enteral-PPI medication doses. In multivariate logistic-regression of switch criteria (any oral-medication, orogastric-tube, nothing by oral route), significant correlate for enteral versus parenteral PPI-use was any oral-medication use but not orogastric-tube. Using enteral esomeprazole/lansoprazole instead of parenteral (esomeprazole/pantoprazole) PPI (in 37% i.e. 696 of 1895 switch-eligible doses) would have saved US2384.17 or US3564.86, respectively. By switching eligible patients on oral-medications or on orogastric-tube from parenteral- to enteral-PPI, institutions can realize significant drug cost-savings.

Original languageEnglish (US)
Pages (from-to)741-749
Number of pages9
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume14
Issue number5
DOIs
StatePublished - Oct 1 2014

Fingerprint

Proton Pump Inhibitors
Intensive Care Units
Small Intestine
Economics
Esomeprazole
Drug Costs
Cost Savings
Lansoprazole
Electronic Health Records
Retrospective Studies
Logistic Models

Keywords

  • acid suppressive agent
  • correlates
  • drug cost saving
  • intensive care
  • intravenous to oral switch

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology (medical)

Cite this

Correlates and economic outcomes of proton pump inhibitor use by routes in intensive care unit patients. / Sankaranarayanan, Jayashri; Reardon, Tom; Olsen, Keith M.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 14, No. 5, 01.10.2014, p. 741-749.

Research output: Contribution to journalArticle

@article{3fcdc00678d742279794a4712d82c7f9,
title = "Correlates and economic outcomes of proton pump inhibitor use by routes in intensive care unit patients",
abstract = "Objectives were to evaluate correlates, and economic outcomes of proton pump inhibitor (PPI) use by route in the intensive care unit from an institutional-payer perspective. A 13-month retrospective study of electronic medical records was conducted of 534 adult (≥19 year-old) intensive care unit patients receiving a PPI (39{\%} enteral-only, 34{\%} parenteral-only, 27{\%} both-route) in a Midwest USA academic medical center. Possible cost-savings with sensitivity analysis were estimated as differences in drug costs (US dollars) between switch eligible parenteral and alternate enteral-PPI medication doses. In multivariate logistic-regression of switch criteria (any oral-medication, orogastric-tube, nothing by oral route), significant correlate for enteral versus parenteral PPI-use was any oral-medication use but not orogastric-tube. Using enteral esomeprazole/lansoprazole instead of parenteral (esomeprazole/pantoprazole) PPI (in 37{\%} i.e. 696 of 1895 switch-eligible doses) would have saved US2384.17 or US3564.86, respectively. By switching eligible patients on oral-medications or on orogastric-tube from parenteral- to enteral-PPI, institutions can realize significant drug cost-savings.",
keywords = "acid suppressive agent, correlates, drug cost saving, intensive care, intravenous to oral switch",
author = "Jayashri Sankaranarayanan and Tom Reardon and Olsen, {Keith M.}",
year = "2014",
month = "10",
day = "1",
doi = "10.1586/14737167.2014.940902",
language = "English (US)",
volume = "14",
pages = "741--749",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Correlates and economic outcomes of proton pump inhibitor use by routes in intensive care unit patients

AU - Sankaranarayanan, Jayashri

AU - Reardon, Tom

AU - Olsen, Keith M.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Objectives were to evaluate correlates, and economic outcomes of proton pump inhibitor (PPI) use by route in the intensive care unit from an institutional-payer perspective. A 13-month retrospective study of electronic medical records was conducted of 534 adult (≥19 year-old) intensive care unit patients receiving a PPI (39% enteral-only, 34% parenteral-only, 27% both-route) in a Midwest USA academic medical center. Possible cost-savings with sensitivity analysis were estimated as differences in drug costs (US dollars) between switch eligible parenteral and alternate enteral-PPI medication doses. In multivariate logistic-regression of switch criteria (any oral-medication, orogastric-tube, nothing by oral route), significant correlate for enteral versus parenteral PPI-use was any oral-medication use but not orogastric-tube. Using enteral esomeprazole/lansoprazole instead of parenteral (esomeprazole/pantoprazole) PPI (in 37% i.e. 696 of 1895 switch-eligible doses) would have saved US2384.17 or US3564.86, respectively. By switching eligible patients on oral-medications or on orogastric-tube from parenteral- to enteral-PPI, institutions can realize significant drug cost-savings.

AB - Objectives were to evaluate correlates, and economic outcomes of proton pump inhibitor (PPI) use by route in the intensive care unit from an institutional-payer perspective. A 13-month retrospective study of electronic medical records was conducted of 534 adult (≥19 year-old) intensive care unit patients receiving a PPI (39% enteral-only, 34% parenteral-only, 27% both-route) in a Midwest USA academic medical center. Possible cost-savings with sensitivity analysis were estimated as differences in drug costs (US dollars) between switch eligible parenteral and alternate enteral-PPI medication doses. In multivariate logistic-regression of switch criteria (any oral-medication, orogastric-tube, nothing by oral route), significant correlate for enteral versus parenteral PPI-use was any oral-medication use but not orogastric-tube. Using enteral esomeprazole/lansoprazole instead of parenteral (esomeprazole/pantoprazole) PPI (in 37% i.e. 696 of 1895 switch-eligible doses) would have saved US2384.17 or US3564.86, respectively. By switching eligible patients on oral-medications or on orogastric-tube from parenteral- to enteral-PPI, institutions can realize significant drug cost-savings.

KW - acid suppressive agent

KW - correlates

KW - drug cost saving

KW - intensive care

KW - intravenous to oral switch

UR - http://www.scopus.com/inward/record.url?scp=84907049662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907049662&partnerID=8YFLogxK

U2 - 10.1586/14737167.2014.940902

DO - 10.1586/14737167.2014.940902

M3 - Article

C2 - 25059290

AN - SCOPUS:84907049662

VL - 14

SP - 741

EP - 749

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 5

ER -